Dialysis Clinical Trial
Official title:
Determination of Citrate Clearance Used in Regional Anticoagulation of Continuous Venous Hemofiltration Circuits
Citrate anticoagulation is becoming the gold standard in dialysis in intensive care units. It is now accepted that citrate prolongs the life of filters with a lower risk of bleeding. However, the management of citrate is complex. Optimization is based on citrate flow, blood flow and the amount of calcium reinjected. Frequently the citrate level is sub-dosed.Currently, the fraction of excretion of citrate by the hemodialysis machine is unknown. Knowing this information would allow, if it is important enough, to add an additional parameter of citrate management by adapting the level of dialysis. The determination of citrate in an extracorporeal circulation circuit has already been performed and has been validated in the literature. We propose to perform the assay on subjects with the same starting parameters, in order to deduce the clearance of citrate.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 1, 2023 |
Est. primary completion date | December 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Intensive care dialysis patients (Continuous Venous Hemofiltration with citrate). Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
Belgium | CHU Brugmann | Brussels |
Lead Sponsor | Collaborator |
---|---|
Dr David DE BELS |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Citrate concentration - pre-filter | Citrate concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Primary | Citrate concentration - post-filter | Citrate concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Primary | Citrate concentration - dialysate | Citrate concentration in a blood sample taken in the dialysate | 30 minutes after the start of dialysis | |
Secondary | Age | Age | Baseline | |
Secondary | Weight | Weight | Baseline | |
Secondary | Height | Height | Baseline | |
Secondary | Sex | Sex | Baseline | |
Secondary | Apache II score | The APACHE II score is calculated at the beginning of the intensive care unit admission to help determine the patient's mortality risk for the admission. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. | Baseline | |
Secondary | SOFA (Sequential Organ Failure Assessment) score | The Sequential Organ Failure Assessment score (SOFA score), is used in intensive care units to determine and track the status of a patient with organ failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. Higher scores mean a higher risk of mortality. | Baseline | |
Secondary | Glomerular filtration rate (GFR) | Glomerular filtration rate | Baseline | |
Secondary | Creatinin level | Creatinin level | Baseline | |
Secondary | Diuresis | Volume of urinary secretion in the last 12 hours | Baseline | |
Secondary | KDIGO classification | The KDIGO classification defines 3 stages of increasing severity for acute kidney injuries. | Baseline | |
Secondary | Na (sodium) concentration -pre-filter | Na (sodium) concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Na (sodium) concentration -post-filter | Na (sodium) concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Cl (chlorine) concentration - pre-filter | Cl (chlorine) concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Cl (chlorine) concentration -post-filter | Cl (chlorine) concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | K (potassium) concentration - pre-filter | K (potassium) concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | K (potassium) concentration - post-filter | K (potassium) concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Total Ca (calcium) concentration -pre-filter | Ca (calcium) concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Total Ca (calcium) concentration -post-filter | Ca (calcium) concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Total Ca (calcium) concentration -dialysate | Ca (calcium) concentration in the dialysate | 30 minutes after the start of dialysis | |
Secondary | Ionized calcium (Ca2+) concentration -pre-filter | Ca (calcium) concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Ionized calcium (Ca2+) concentration -post-filter | Ca (calcium) concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Ionized calcium (Ca2+) concentration -dialysate | Ca (calcium) concentration in the dialysate | 30 minutes after the start of dialysis | |
Secondary | Mg (magnesium) concentration - pre-filter | Mg (magnesium) concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Mg (magnesium) concentration - post-filter | Mg (magnesium) concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | PO4 (phosphate) concentration - pre-filter | PO4 (phosphate) concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | PO4 (phosphate) concentration - post-filter | PO4 (phosphate) concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Lactate concentration - pre-filter | Lactate blood concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Lactate concentration - post-filter | Lactate blood concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Albumin concentration -pre-filter | Albumin concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Albumin concentration -post-filter | Albumin concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | pH - pre-filter | pH of a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | pH - post-filter | pH of a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Total C-reactive protein (CRP) -pre-filter | Total CRP concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Total C-reactive protein (CRP) -post-filter | Total CRP concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Total C-reactive protein (CRP) -dialysate | Total CRP concentration in a blood sample taken in the dialysate | 30 minutes after the start of dialysis | |
Secondary | Monomeric C-reactive protein (CRP) -pre-filter | Monomeric CRP concentration in a blood sample taken before the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Monomeric C-reactive protein (CRP) -post-filter | Monomeric CRP concentration in a blood sample taken after the dialysis filter | 30 minutes after the start of dialysis | |
Secondary | Monomeric C-reactive protein (CRP) -dialysate | Monomeric CRP concentration in a blood sample taken in the dialysate | 30 minutes after the start of dialysis |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05031013 -
Trace Elements Concentration in Dialysis
|
||
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Completed |
NCT01685372 -
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
|
Phase 2 | |
Active, not recruiting |
NCT01394770 -
Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients
|
Phase 4 | |
Completed |
NCT00506441 -
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
|
Phase 3 | |
Completed |
NCT00537979 -
Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
|
Phase 4 | |
Completed |
NCT05415969 -
CKD-aP Among Adults on Dialysis in Switzerland
|
||
Completed |
NCT03772171 -
Estimate for Dietary Intakes and Hemodialysis Patients
|
||
Recruiting |
NCT02586402 -
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
|
Phase 2 | |
Active, not recruiting |
NCT01693263 -
Outcome of BCF Access in Hemodialysis Patients
|
||
Completed |
NCT01421771 -
Blood Pressure in Dialysis Patients
|
N/A | |
Active, not recruiting |
NCT01065389 -
Resistance Training in Intradialysis Patients
|
Phase 2 | |
Completed |
NCT00544492 -
Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT03910426 -
Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients
|
||
Completed |
NCT04565522 -
Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers
|
||
Completed |
NCT04667741 -
Post-dialysis Recovery Time and Affecting Factors Between Turkey and Portugal
|
||
Completed |
NCT04655989 -
A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System
|
N/A | |
Completed |
NCT05125848 -
Clinical Evaluation of the CM-1500 During Hemodialysis
|
N/A | |
Completed |
NCT04633915 -
Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.
|
||
Completed |
NCT00767897 -
The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients
|